Efficacy of intravenous alfacalcidol in the treatment of secondary hyperparathyroidism in patients on hemodialysis

Nephron - Clinical Practice

Volumn 108, Issue 2, 2008, Pages

  Gonzalez M T ^a   Torregrosa, J V ^b   Colome E ^c   Mendia, A ^c   Pavesi, M ^d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Laboratorios LEO Pharma SA   (Spain)

^d INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Alfacalcidol; Hemodialysis; K DOQI guidelines; Renal osteodystrophy; Secondary hyperparathyroidism

Indexed keywords

ALFACALCIDOL; CALCIUM; COLECALCIFEROL; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROSPECTIVE STUDIES; REFERENCE VALUES; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 40449123417     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000115326     Document Type: Article

References (23)

1. 3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Nephron 1995;71:254-283.
2. Malluche HH, Maward H, Monier-Faugere MC: The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? Nephrol Dial Transplant 2004;19(suppl 1):9-13.
3. Goodman WG: Importance of hyperphosphataemia in the cardio-renal axis. Nephrol Dial Transplant 2004;19(suppl 1):14-18.
4. Mawer EB, Taylor CM, Backhouse J, Lumb GA, Stanbury SW: Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet 1974;i:626-628.
5. Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G: Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. J Nephrol 2006;19:566-577.
6. 3 treatment of secondary hyperparathyroidism in uraemia. J Intern Med 1996;239:353-360.
7. 3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic haemodialysis. Nephron 1996;74:89-103.
8. 3 and low dialysate calcium. Kidney Int 1993;41:S121-S124.
9. Cannata JB: Indications and limitations of intravenous calcitriol. Nefrología 1995;55:307-314.
10. Wang M, Hercz G, Sherrard DJ, Maloney NA, Serge GV, Pei Y: Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836-844.
11. Diaz-Corte C, Naves ML, Rodríguez A, et al: Renal osteodystrophy in Spain. Multicenter survey. I. Collaborative Centers of the Multicenter Study on Renal Osteodystrophy. Nefrologia 2000;20:234-243.
12. Young EW, Akiba T, Albert JM, et al: Magnitude and impact of abnormal mineral metabolism in haemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2004;44:(suppl 3):S34-S38.
13. Maduell F, Gorriz JL, Pallardo LM, Pons R, Santiago C: Assessment of phosphorous and calcium metabolism and its clinical management in haemodialysis patients in the community of Valencia. J Nephrol 2005;18:739-748.
14. Arenas MD, Alvarez-Ude F, Gil MT, et al: Application of NKF-K/DOQI clinical practice guidelines for bone metabolism and disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 2006;21:1663-1668.
15. Lorenzo V, Martín-Malo A, Pérez-García R, et al: Prevalence, clinical correlation and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial Transplant 2006;21:459-465.
16. Diaz-Corte C, Rodríguez A, Naves ML, et al: Bone metabolic markers and use of vitamin D in dialysis. Multicenter survey. II. Collaborative Centers of the Multicenter Study on Renal Osteodystrophy. Nefrologia 2000;20:244-253.
17. Fernández F, Llach F: Guidelines for dosing of intravenous calcitriol in dialysis patients with hyperparathyroidism. Nephrol Dial Transplant 1996;11(suppl 3):96-101.
18. Goicoechea M, Pérez García R, Vázquez MI, Ruiz MA, Vozmediano MC, Valderrábano F: Intravenous calcitriol in secondary hyperparathyroidism: what are the factors related to a lack of response? Nefrología 1996;56:531-538.
19. Albaaj F, Hutchison AJ: Hyperphosphataemia in renal failure: causes, consequences and current management. Drugs 2003;63:577-596.
20. Qunibi WY, Nolan CR: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study. Kidney Int 2004;66(suppl 90):S33-S38.
21. Argilès A, Herr PG, Canaud B, Flavier JL: Calcium kinetics and long-term effects of lowering dialysate calcium concentrations. Kidney Int 1993;43:630-640.
22. Van der Niepen P, Sennesael J, Louis O, Verbeelen D: Effect of treatment with 1.25 and 1.75 mmol/l calcium dialysate on bone mineral density in hemodialysis patients. Nephrol Dial Transplant 1995;10:2253-2258.
23. Llach F, Hervas J, Cerezo S: The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis 1995;26:845-851.